HCV Treatment with Sofosbuvir in Pakistan; Current Scenario and Future Perspective
Abstract
Keywords
References
Ravi S, Nasiri-Toosi M, Karimzadeh I, Khalili H, Ahadi-Barzoki M, Dashti-Khavidaki S. Pattern and associated factors of anti-hepatitis C virus treatment induced adverse reactions. Expert Opin Drug Saf 2014; 13:277–286.
WHO. 2017. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed on 5th Feb 2018)
Afzal MS. (2016). Are efforts up to the mark? A cirrhotic state and knowledge about HCV prevalence in general population of Pakistan. Asian Pac J Trop Med. 9(6):616-8. doi: 10.1016/j.apjtm.2016.04.013.
Arshad A, Ashfaq UA. (2017). Epidemiology of Hepatitis C Infection in Pakistan: Current Estimate and Major Risk Factors. Crit Rev Eukaryot Gene Expr. 27(1):63-77. doi: 10.1615/CritRevEukaryotGeneExpr.2017018953.
Umer M and Iqbal M. (2016). Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol. 22(4): 1684–1700.
Afzal MS, Iqbal MA. (2017). Hepatitis C Virus in Pakistan: Community Education Is an Effective Weapon Against the Killer. Viral Immunol. 30(8):548-551. doi: 10.1089/vim.2016.0171.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. (2015). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 61(1):77-87. doi: 10.1002/hep.27259.
Afzal MS. (2017). Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan. Viral Immunol. 30(4):252-257. doi: 10.1089/vim.2016.0164.
Afzal MS, Shah ZH, Ahmed H. (2016). Recent HCV genotype changing pattern in the Khyber Pakhtunkhwa province of Pakistan; is it pointing out a forthcoming problem? Braz J Infect Dis. 20(3):312-3. doi: 10.1016/j.bjid.2015.12.011.
Kanda T, Imazeki F, Yokosuka O. (2010). New antiviral therapies for chronic hepatitis C. Hepatol Int. 4:548–561.
Afzal MS. (2016). Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol. 8(26): 1116–1118. doi: 10.4254/wjh.v8.i26.1116.
Akhter TS, Umar M, Khaar HT, Aslam F, Nisar G, Naseer A, Ahmad S, Osama M. (2016). Sofosbuvir for the treatment of hepatitis c genotype 3 infected patients in Pakistan. J Ayub Med Coll Abbottabad. 28(4 Suppl 1):S884-S889.
Capileno YA, Van den Bergh R, Donchuk D, Hinderaker SG, Hamid S, Auat R, Khalid GG, Fatima R, Yaqoob A, Van Overloop C. (2017). Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan. PLoS One. 12(6):e0180286. doi: 10.1371/journal.pone.0180286.
Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. (2017). Rapid virological & End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pak J Med Sci. 33(4):813-817. doi: https://doi.org/10.12669/pjms.334.12785.
Azam Z, Shoaib M, Javed M, Sarwarm MA, Shaikh H, Khokhar N. (2017). Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS). Pak J Med Sci. 33(1):48-52. doi: https://doi.org/10.12669/pjms.331.12352
Sarwar S, Khan AA. (2017). Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference? Pak J Med Sci. 33(1):37-41. doi: https://doi.org/10.12669/pjms.331.12163
Munir B, Ahmed B, Kiran S, Jalal F, Zahoor MK, Shehzadi S, Oranab S, Kamran SK, Ghaffar A. (2017). Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer. Pak J Pharm Sci. 30(6(Supplementary)):2383-2387.
Iqbal S, Yousuf MH, Yousaf MI.(2017). Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvirbased therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol. 23(44):7899-7905. doi: 10.3748/wjg.v23.i44.7899.
Hanif FM, Laeeq SM, Mandhwani RK, Luck NH, Aziz T, Mehdi SH. (2017). Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce. Exp Clin Transplant. 15(Suppl 1):63-67.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.